EcoDrugPlus

Hck Proto-Oncogene, Src Family Tyrosine Kinase

Ensembl ID : ENSTBEG00000003758
Gene Symbol: HCK
1 Cross references
205 Possible Orthologues:

Il2 Inducible T Cell Kinase

Ensembl ID : ENSTBEG00000009403
Gene Symbol: ITK
1 Cross references
207 Possible Orthologues:

Janus Kinase 1

Ensembl ID : ENSTBEG00000001100
Gene Symbol: JAK1
1 Cross references
236 Possible Orthologues:

Janus Kinase 2

Ensembl ID : ENSTBEG00000001552
Gene Symbol: JAK2
1 Cross references
265 Possible Orthologues:

Kit Proto-Oncogene, Receptor Tyrosine Kinase

Ensembl ID : ENSTBEG00000002212
Gene Symbol: KIT
1 Cross references
265 Possible Orthologues:

Kras Proto-Oncogene, Gtpase

Ensembl ID : ENSTBEG00000003830
Gene Symbol: KRAS
1 Cross references
203 Possible Orthologues:

Lck Proto-Oncogene, Src Family Tyrosine Kinase

Ensembl ID : ENSTBEG00000017267
Gene Symbol: LCK
1 Cross references
120 Possible Orthologues:

Lyn Proto-Oncogene, Src Family Tyrosine Kinase

Ensembl ID : ENSTBEG00000007268
Gene Symbol: LYN
1 Cross references
202 Possible Orthologues:

Mapk Activated Protein Kinase 2

Ensembl ID : ENSTBEG00000012335
Gene Symbol: MAPKAPK2
1 Cross references
233 Possible Orthologues:

Mcl1 Apoptosis Regulator, Bcl2 Family Member

Ensembl ID : ENSTBEG00000006568
Gene Symbol: MCL1
1 Cross references
240 Possible Orthologues:

Mdm2 Proto-Oncogene

Ensembl ID : ENSTBEG00000013758
Gene Symbol: MDM2
1 Cross references
258 Possible Orthologues:

Met Proto-Oncogene, Receptor Tyrosine Kinase

Ensembl ID : ENSTBEG00000006549
Gene Symbol: MET
1 Cross references
211 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).